Live updates: Trump gives speech on U.S. economy, tariffs to crowd of Pennsylvania supporters

President Trump delivered a 90+ minute, campaign-style economic address in Pennsylvania touting tariffs, tax cuts and deregulation as drivers of "lower prices, bigger paychecks," saying $12 billion in recent farm aid was funded by tariff revenue and signaling a litmus test for a Fed chair who would back rapid rate cuts—remarks that could shift market expectations on monetary policy, trade and energy; Treasury Secretary Scott Bessent expressed optimism for 2026. The administration also announced a proposed settlement to end the Biden-era SAVE student loan program and move borrowers into other plans, while the FDA opened a safety review of two infant RSV drugs from Sanofi/AZ and Merck, each carrying distinct credit and sector implications. Meanwhile, the Supreme Court heard a consequential campaign-finance case that could alter party-candidate coordination rules, Democrats flipped the Miami mayoralty (Eileen Higgins 59%–41%), and escalatory rhetoric on Venezuela alongside calls for greater transparency around recent military strikes add near-term geopolitical policy risk for investors.

Analysis

President Trump delivered a 90-plus minute, campaign-style economic address in northeastern Pennsylvania emphasizing tariffs, tax cuts and deregulation as drivers of “lower prices, bigger paychecks,” claimed a $12 billion farm-aid package was funded by tariff revenue, and signaled a litmus test for a Fed chair who would support rapid interest-rate cuts; Treasury Secretary Scott Bessent voiced optimism for a stronger 2026 economy even as an NBC poll found two-thirds of respondents say the administration has fallen short on inflation and affordability. The White House announced a proposed settlement that would end the Biden-era SAVE student loan repayment plan and move borrowers into alternative plans, and the Supreme Court is weighing a campaign-finance case that could materially alter party-candidate coordination rules and expand presidential authority, adding policy and legal uncertainty. The FDA has opened a safety review of two infant RSV products—Beyfortus (Sanofi/AZ) and Enflonsia (Merck)—with no reported safety issues but clear headline risk that aligns with slightly negative per-ticker sentiment for SNY, AZN and MRK. Geopolitical rhetoric—threats regarding Venezuela and pressure over military boat-strike transparency—raises short-term risk to energy and defense-related assets, while Democrats flipping the Miami mayoralty underscores domestic political shifts that could influence regulatory and fiscal dynamics ahead of next year’s midterms.

Key Decisions for Investors

• Reassess near-term exposure to Sanofi (SNY), AstraZeneca (AZN) and Merck (MRK) until the FDA completes its RSV safety review; consider trimming or hedging positions to mitigate headline-driven downside
• Monitor signals on Fed leadership and tariff policy closely; if rhetoric increases odds of earlier rate cuts or broader tariff use, reduce interest-rate duration risk and reweight toward cyclicals sensitive to trade/readjust commodity exposure accordingly
• Watch consumer affordability indicators and midterm political developments (polls, local election flips) as they will drive fiscal and regulatory positioning; favor defensive consumer staples or high-quality cash-flow names if affordability remains pressured
• Price in near-term geopolitical risk around Venezuela and boat-strike scrutiny by using short-duration hedges or options in energy and defense exposures ahead of potential supply or policy shocks